5 extracellular signalling Flashcards

1
Q

What are the five types of extracellular signalling?

A

Endocrine, Neuronal, Paracrine, Autocrine, Contact-Dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does endocrine signalling work?

A

Hormones travel through the bloodstream to act on distant target cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is neuronal signalling?

A

Neurotransmitters are released across synapses to communicate between neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does paracrine signalling function?

A

Local mediators act on nearby target cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is autocrine signalling?

A

A cell releases signals that act on itself (e.g. growth factors).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does contact-dependent signalling work?

A

A signalling cell directly contacts the target cell via membrane-bound molecules (e.g. Notch signalling).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are mitogenic signalling molecules?

A

Growth factors (GFs) that stimulate cell division.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do growth factors interact with cells?

A

They bind to cell surface receptors to regulate functions like migration, replication, and survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the role of Fibroblast Growth Factor (FGF) in cancer?

A

FGF8 and FGF17 are overexpressed in prostate cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is angiogenesis, and how does VEGF contribute to it?

A

Angiogenesis is the formation of new blood vessels, driven by VEGF in tumour cells to meet oxygen demands.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does FGF1 affect colorectal cancer?

A

Higher FGF1 expression correlates with reduced survival; decreasing FGF1 downregulates tumour growth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What do growth factor receptors do?

A

They receive extracellular signals and initiate intracellular signalling cascades.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are receptor tyrosine kinases (RTKs)?

A

RTKs are receptors that transmit GF signals via phosphorylation cascades.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the main structural components of RTKs?

A

Growth Factor Binding Site, Transmembrane Domain, Catalytic Region, Target Tyrosine Residues, Extracellular Domain, Intracellular Domain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the four steps in RTK activation?

A

Ligand binding, receptor dimerisation, kinase domain activation, transphosphorylation of tyrosine residues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the role of phospho-tyrosines in RTK signalling?

A

They recruit adaptor proteins that initiate downstream cascades.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are SH2 domains?

A

Protein modules that bind to phospho-tyrosine residues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is Ras, and what does it do?

A

A small GTPase that regulates MAPK signalling.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the three isoforms of Ras?

A

H-Ras, N-Ras, and K-Ras.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What happens when Ras is GTP-bound?

A

It activates Raf, initiating the MAPK phosphorylation cascade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the archetypal MAPK pathway?

A

Ras-GTP → Raf → MEK → ERK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the five conventional MAPK pathways?

A

ERK, JNK, p38, ERK3/4, ERK5.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What stimuli activate ERK, JNK, and p38 pathways?

A

ERK: Growth factors; JNK: Stress stimuli; p38: Stress, TGF-β, cytokines.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are key ERK1/2 substrates?

A

Elk-1, c-Myc, c-Fos, c-Jun.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How does Raf activate MEK?

A

By phosphorylating it on two serine residues (S218/S222).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How does MEK activate ERK?

A

By phosphorylating it on threonine and tyrosine residues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What role do ERK1/2 play in apoptosis?

A

They phosphorylate pro-apoptotic proteins (BMF, BIM, BIK) to degrade them.

28
Q

What percentage of oncogenes encode tyrosine kinases?

29
Q

What are key oncogenes in the MAPK pathway?

A

Ras, c-Myc, c-Fos, c-Jun.

30
Q

How do RTKs normally get downregulated?

A

Through clathrin-mediated endocytosis and degradation/recycling

31
Q

What is HIP1, and why is it upregulated in cancer?

A

A protein involved in RTK recycling that is overexpressed in colon and prostate cancers.

32
Q

What are Sprouty 2 and Kekkon 1?

A

Negative regulators of RTK signalling.

33
Q

What happens when Sprouty 2 levels decrease?

A

Increased Ras activation and tumour progression.

34
Q

How does phosphorylation-dependent feedback regulate ERK?

A

Phosphorylation of EGFR and Raf reduces their activity.

35
Q

What is Trastuzumab (Herceptin)?

A

A HER2-targeting antibody therapy for breast cancer.

36
Q

How does Trastuzumab inhibit HER2?

A

Prevents ligand binding, dimerisation, and promotes antibody-dependent cytotoxicity (ADCC).

37
Q

How does Trastuzumab impact ERK signalling?

A

Reduces ERK1/2 phosphorylation and tumour growth.

38
Q

What is Erdafitinib (Balversa)?

A

An FGFR inhibitor used in cancer therapy.

39
Q

What does Erdafitinib target?

A

The ATP-binding pocket of FGFRs.

40
Q

How does Erdafitinib affect cancer cells?

A

Reduces FGFR phosphorylation and downstream ERK activation.

41
Q

Why is resistance to FGFR inhibitors a concern?

A

Cancer cells can re-activate RTK signalling via alternative pathways.

42
Q

What is the IC50 value?

A

The concentration required to inhibit enzyme activity by 50%.

43
Q

How do RTK inhibitors initially impact cancer cells?

A

They reduce MAPK signalling but can lose effectiveness over time.

44
Q

What is ADCC?

A

Antibody-dependent cellular cytotoxicity, a mechanism used by immune cells to kill antibody-tagged cancer cells.

45
Q

Why is HER2 overexpression problematic?

A

It leads to excessive RTK signalling and uncontrolled cell proliferation.

46
Q

What is the significance of KRAS mutations in cancer?

A

They cause hyperactive Ras-ERK signalling, leading to tumour growth.

47
Q

What cancers have high KRAS mutation rates?

A

Colon (45%), Pancreas (90%), NSCLC (35%)

48
Q

How do negative feedback mechanisms affect RTK inhibitors?

A

Loss of feedback inhibition can restore ERK1/2 signalling.

49
Q

What are early response genes in MAPK signalling?

A

c-Fos, c-Jun, c-Myc.

50
Q

What are late response genes in MAPK signalling?

A

Cyclins and cyclin-dependent kinases (CDKs).

51
Q

How does ERK1/2 phosphorylation provide negative feedback on the MAPK pathway?

A

ERK1/2 phosphorylates multiple targets to reduce signalling:

EGFR: Phosphorylation at T669 blocks RTK activity.
Raf: Phosphorylation at S29, S289, S296, S301, S642 reduces Ras-Raf binding.
Sprouty & Kekkon: ERK activation leads to their expression, which represses RTK signalling.
DUSP Phosphatases: ERK1/2 upregulates dual-specificity phosphatases (DUSPs) that dephosphorylate MAPKs, inhibiting the pathway.

52
Q

What role do DUSP phosphatases play in MAPK regulation?

A

DUSP (Dual-Specificity Phosphatases) dephosphorylate ERK1/2, reducing its activation and controlling signal duration.

53
Q

How does Sprouty 2 (Spry2) inhibit RTK signalling?

A

Spry2 indirectly inhibits Ras activation by interfering with adaptor proteins like Grb2, preventing Ras-GTP loading.

54
Q

How does Kekkon 1 (Kek1) block RTK signalling?

A

Kek1 directly binds RTKs and prevents GF binding and dimerisation, acting as a competitive inhibitor.

55
Q

Why is the loss of Spry2 linked to cancer progression?

A

Decreased Spry2 expression removes a key negative feedback mechanism, leading to uncontrolled MAPK activation and tumour growth.

56
Q

What is the role of CBL in RTK regulation?

A

CBL is an E3 ubiquitin ligase that tags active RTKs for endocytosis and degradation, preventing excessive signalling.

57
Q

How does endocytosis regulate RTK signalling?

A

RTKs are internalised into endosomes. Depending on signalling needs, they are either:

Recycled back to the plasma membrane (prolongs signalling).
Degraded in lysosomes (terminates signalling).

58
Q

How does Rab5 regulate RTK trafficking?

A

Rab5 is a small GTPase that controls the early steps of endosome formation and RTK sorting, influencing signal duration.

59
Q

What mechanisms drive resistance to Erdafitinib (FGFR inhibitor)?

A

Compensatory Pathway Activation: Tumours upregulate PI3K-AKT or JAK-STAT to bypass FGFR inhibition.
Secondary FGFR Mutations: Some FGFR mutations reduce Erdafitinib binding, making the drug less effective.
Increased FGFR Expression: Cells may increase FGFR levels to outcompete the inhibitor.

60
Q

How do cancer cells develop resistance to Trastuzumab (Herceptin)?

A

HER2 Mutations: Some tumours develop mutations in HER2 that prevent Trastuzumab from binding.
Compensatory RTK Activation: Other RTKs (EGFR, IGF-1R) can reactivate MAPK even when HER2 is blocked.
Altered HER2 Trafficking: Changes in HER2 endocytosis reduce degradation, prolonging signalling.
Loss of ADCC Response: Tumours may downregulate Fc receptors on immune cells, reducing antibody-dependent cytotoxicity.

61
Q

What MEK mutations contribute to cancer?

A

MEK1/2 mutations (e.g. MEK1 F53L, MEK1 Q56P) increase kinase activity, leading to constitutive ERK activation.

62
Q

How do Raf mutations differ in their effects?

A

B-Raf V600E: Constitutively active, drives melanoma.
C-Raf mutations: Less common, often cooperate with Ras mutations.

63
Q

Why do Ras and Raf mutations lead to therapy resistance?

A

Ras mutations prevent GTP hydrolysis, locking Ras in the active state.
B-Raf mutations bypass upstream signals, making RTK inhibitors ineffective.

64
Q

What is the role of PDGF (Platelet-Derived Growth Factor)?

A

PDGF activates RTKs to stimulate fibroblast proliferation, wound healing, and tumour stroma formation.

65
Q

How does IGF (Insulin-Like Growth Factor) contribute to cancer?

A

IGF-1R signalling activates MAPK & PI3K-AKT pathways, promoting growth and survival in cancers like breast and prostate cancer.

66
Q

What are key differences between VEGF and FGF in angiogenesis?

A

VEGF: Primarily stimulates endothelial cells to form blood vessels.
FGF: Stimulates both endothelial & stromal cells, leading to wider tissue remodelling.